poisar

Stocks · News reference

AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo

Benzinga Newsdesk

These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  2. Sns Insider

    Skin Boosters Market Expands as Regenerative PDRN Formulations Broaden Minimally Invasive Aesthetics

    The global skin boosters market is experiencing significant growth driven by increasing consumer demand for minimally invasive aesthetic procedures. The market, valued at $1.40 billion in 2025, is projected to reach $4.30 billion by 2035, with a CAGR of 11.89%. Growth is fueled by expanding medspa access, regenerative ingredients like PDRN, and rising awareness of hyaluronic acid treatments. The U.S. market is expected to grow from $0.36 billion to $1.08 billion, while Asia Pacific shows the highest growth potential at 12.70% CAGR.

    ABBVGALDY
  4. Robert Izquierdo

    Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

    The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

    IBBQIYHLLYJNJABBV